Perennial Allergic Rhinitis Study In Pediatric Subjects
NCT ID: NCT00108914
Last Updated: 2017-01-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
558 participants
INTERVENTIONAL
2005-02-28
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Seasonal Allergic Rhinitis In Pediatric Subjects
NCT00107757
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
NCT00289198
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
NCT00116883
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.
NCT00225823
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
NCT00103454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GW685698X
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of corticosteroids or other allergy medications during the study.
* Have abnormal ECG.
* Have laboratory abnormality.
* Have abnormal eye exam.
2 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Costa Mesa, California, United States
GSK Investigational Site
Cudahy, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Riverside, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Walnut Creek, California, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Englewood, Colorado, United States
GSK Investigational Site
Coral Gables, Florida, United States
GSK Investigational Site
Gainesville, Georgia, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Stockbridge, Georgia, United States
GSK Investigational Site
Metairie, Louisiana, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Ypsilanti, Michigan, United States
GSK Investigational Site
Jackson, Mississippi, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Brick, New Jersey, United States
GSK Investigational Site
Ithaca, New York, United States
GSK Investigational Site
Liverpool, New York, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Utica, New York, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Lake Oswego, Oregon, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Bellevue, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Upland, Pennsylvania, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Knoxville, Tennessee, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
El Paso, Texas, United States
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Nueve de Julio, Buenos Aires, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
GSK Investigational Site
Santa Fe, Santa Fe Province, Argentina
GSK Investigational Site
Viña del Mar, Región de Valparaíso, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Joensuu, , Finland
GSK Investigational Site
Nokia, , Finland
GSK Investigational Site
Tampere, , Finland
GSK Investigational Site
Turku, , Finland
GSK Investigational Site
Napoli, Campania, Italy
GSK Investigational Site
Bari, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Monticelli Ascoli Piceno, , Italy
GSK Investigational Site
Perugia, , Italy
GSK Investigational Site
Salerno, , Italy
GSK Investigational Site
México, , Mexico
GSK Investigational Site
México, , Mexico
GSK Investigational Site
Monterrey, N.L, , Mexico
GSK Investigational Site
Banská Bystrica, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Levoča, , Slovakia
GSK Investigational Site
Nitra, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Máspero J, Rosenblut A, Finn A, J Lim J, Wu W, Philpot E. Safety of fluticasone furoate* nasal spray in children with perennial allergic rhinitis (*USAN approved name). Allergy 2007;62(Suppl. 83): 381 (abstract).
Máspero JF, Rosenblut A, Finn A, Lim J, Wu W, Faris M, Philpot E. Once-daily fluticasone furoate nasal spray (FF) is safe and effective in the long-term treatment of perennial allergic rhinitis (PAR) in children ages 2 to 11 years. J Allergy Clin Immunol.
Maspero JF, Rosenblut A, Finn A Jr, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008 Jan;138(1):30-7. doi: 10.1016/j.otohns.2007.10.023.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FFR30008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.